Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Linezolid
Drug ID BADD_D01295
Description Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci.[L32965] Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit[A11227,A199050] and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction. Linezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class.[A233425] A second member of this class, [tedizolid], was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.
Indications and Usage For the treatment of bacterial infections caused by susceptible strains of vancomycin resistant Enterococcus faecium, Staphylococcal aureus (methicillin resistant and susceptible strains), Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae.
Marketing Status Prescription; Discontinued
ATC Code J01XX08
DrugBank ID DB00601
KEGG ID D00947
MeSH ID D000069349
PubChem ID 441401
TTD Drug ID D07UYO
NDC Product Code 62332-183; 66794-219; 0904-6553; 0009-5137; 59762-1308; 68382-413; 67457-324; 66499-0047; 63323-713; 55111-947; 46708-936; 0781-3431; 0409-4883; 0009-5140; 63629-8576; 73377-115; 65841-166; 60687-309; 57664-683; 66022-0103; 70518-1226; 68578-0009; 66022-0201; 31722-749; 59762-1307; 73309-004; 59285-021; 66794-236; 65427-821; 0054-0319; 65162-777; 46708-861; 72606-001; 70771-1111; 40032-022; 46708-183; 62512-0032; 66022-0206; 0009-4992; 58623-0129; 66298-7131; 55150-242; 66298-5137; 0009-5157; 58032-2009; 67457-843; 66039-825; 66298-5140; 57664-682; 66298-7807; 52562-019; 67877-419; 0009-5138; 0781-3433; 0009-7807; 68724-5135; 25021-169; 0009-5136
Synonyms Linezolid | N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide | Linezolide | Zyvox | U 100766 | 100766, U | PNU-100766 | PNU 100766 | PNU100766 | U-100766 | U100766
Chemical Information
Molecular Formula C16H20FN3O4
CAS Registry Number 165800-03-3
SMILES CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gangrene24.04.05.003; 11.02.01.003; 23.06.06.0010.015094%Not Available
Gastric ulcer07.04.03.0020.011320%
Gastritis07.08.02.001--
Gastrointestinal carcinoma16.13.04.001; 07.21.03.0010.002953%Not Available
Gastrointestinal disorder07.11.01.0010.045281%Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Gastrointestinal pain07.01.05.005--
Generalised oedema14.05.06.007; 08.01.07.004--
Generalised tonic-clonic seizure17.12.01.002--Not Available
Glossitis07.14.01.0010.018867%Not Available
Haematoma24.07.01.001--
Haematuria24.07.01.047; 20.02.01.006--
Haemoglobin13.01.05.018--Not Available
Haemoglobin abnormal13.01.05.0110.007547%Not Available
Haemoglobin decreased13.01.05.0030.094335%Not Available
Haemoptysis24.07.01.006; 22.02.03.004; 02.01.02.0060.015094%Not Available
Haemorrhage subcutaneous24.07.06.010; 23.06.07.0020.007547%Not Available
Hallucination19.10.02.0020.064148%
Headache17.14.01.001--
Heart rate increased13.14.04.002--Not Available
Hepatic cirrhosis09.01.04.0010.002953%Not Available
Hepatic failure09.01.03.002--
Hepatic function abnormal09.01.02.0010.030187%Not Available
Hepatitis09.01.07.0040.015094%Not Available
Hepatitis acute09.01.07.0050.011320%Not Available
Hepatitis cholestatic09.01.01.0020.015094%Not Available
Hepatocellular injury09.01.07.0080.011320%Not Available
Hepatomegaly09.01.05.0010.007547%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.0090.030187%Not Available
Hyperbilirubinaemia09.01.01.003; 01.06.04.003; 14.11.01.0100.007547%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 13 Pages